Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR19-BCMA CAR-T in Relapsed/Refractory Multiple Myeloma
NCT07249073Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T + anti-BCMA CAR-T in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Incidence and Severity of Adverse Events at 3 months and Laboratory tests at 3 months. Started Mar 2025; status: recruiting.
02
Drugs
anti-CD19 CAR-T + anti-BCMA CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07249073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07249073.